Dow Jones Industrial Average
) is trading up 288 points (+2.4%) at 12,054 as of Tuesday, Dec 20, 2011, 12:35 p.m. ET. During this time, 404.6 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 899 million. The NYSE advances/declines ratio sits at 2,646 issues advancing vs. 349 declining with 65 unchanged.
The Dow component leading the way higher looks to be
), which is sporting a 14-cent gain (+0.6%) bringing the stock to $21.28. This single gain is lifting the Dow Jones Industrial Average by 1.06 points or roughly accounting for 0.4% of the Dow's overall gain. Volume for Pfizer currently sits at 27.1 million shares traded vs. an average daily trading volume of 47.5 million shares.
Pfizer has a market cap of $161.66 billion and is part of the
industry. Shares are up 20.7% year to date as of Monday's close. The stock's dividend yield sits at 4.2%.
Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company has a P/E ratio of 16.6, above the average drugs industry P/E ratio of 14.5 and below the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates Pfizer as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, attractive valuation levels and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.
- You can view the full Pfizer Ratings Report.